Literature DB >> 8364927

Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.

Z Fan1, H Masui, I Altas, J Mendelsohn.   

Abstract

We have previously described anti-epidermal growth factor (EGF) receptor monoclonal antibodies (MAbs) which can block binding of transforming growth factor alpha (TGF-alpha) and EGF to receptors and inhibit activation of receptor tyrosine kinase. Studies with these MAbs involving cell cultures and nude mouse xenografts demonstrated their capacity to inhibit the growth of a variety of tumor cell lines, which express EGF receptors and TGF-alpha and appear to depend upon receptor activation for cell proliferation. To explore the mechanism(s) by which anti-EGF receptor 225 MAb inhibits cell proliferation, we have compared the activity of native 225 MAb with the response to bivalent 225 F(ab')2 and monovalent 225 Fab' fragments. Both native 225 MAb and its fragments could inhibit the binding of 125I-EGF to EGF receptors. Scatchard analysis revealed that the Kd of 225 F(ab')2 is comparable to that of 225 MAb (1 nM), whereas the Kd of 225 Fab' is 5 nM. Both bivalent 225 MAb and 225 F(ab')2 and monovalent 225 Fab' were able to completely inhibit TGF-alpha-induced EGF receptor tyrosine kinase activation, as assayed by autophosphorylation of tyrosine residues of EGF receptors on MCF10A nonmalignant human mammary cells, MDA468 human breast adenocarcinoma cells, and A431 human vulvar squamous carcinoma cells. The bivalent forms of MAb could inhibit proliferation stimulated by endogenous (autocrine) TGF-alpha in cultures of these three cell lines. They also blocked growth stimulation by added exogenous TGF-alpha in cultures of MCF10A cells and the growth-inhibitory effect of exogenous TGF-alpha upon MDA468 and A431 cell cultures. Monovalent 225 Fab' had weaker inhibitory effects upon the proliferation of these cell lines. To determine whether the in vivo antiproliferative activity of anti-EGF receptor MAb can occur without the participation of the Fc portion of MAb, the capacities of 225 F(ab')2 and native 225 MAb to inhibit growth of s.c. A431 cell xenografts were compared. Equimolar amounts of either 225 MAb or 225 F(ab')2 were administered at intervals equivalent to the half-lives of the molecules, to attempt to maintain comparable plasma levels. Both 225 MAb and 225 F(ab')2 inhibited A431 cell xenograft growth in a dose-dependent manner, with a more sustained response in the case of the intact antibody.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8364927

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

1.  Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo.

Authors:  N S Soukos; M R Hamblin; S Keel; R L Fabian; T F Deutsch; T Hasan
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

2.  Roles of autophagy in cetuximab-mediated cancer therapy against EGFR.

Authors:  Xinqun Li; Yang Lu; Tianhong Pan; Zhen Fan
Journal:  Autophagy       Date:  2010-11       Impact factor: 16.016

3.  Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.

Authors:  Eric Luedke; Alena Cristina Jaime-Ramirez; Neela Bhave; Julie Roda; Moaz Maqbool Choudhary; Bhavna Kumar; Theodoros N Teknos; William E Carson
Journal:  Surgery       Date:  2012-07-06       Impact factor: 3.982

4.  AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

Authors:  Moshe Elkabets; Evangelos Pazarentzos; Dejan Juric; Qing Sheng; Raphael A Pelossof; Samuel Brook; Ana Oaknin Benzaken; Jordi Rodon; Natasha Morse; Jenny Jiacheng Yan; Manway Liu; Rita Das; Yan Chen; Angela Tam; Huiqin Wang; Jinsheng Liang; Joseph M Gurski; Darcy A Kerr; Rafael Rosell; Cristina Teixidó; Alan Huang; Ronald A Ghossein; Neal Rosen; Trever G Bivona; Maurizio Scaltriti; José Baselga
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

5.  The airways, a novel route for delivering monoclonal antibodies to treat lung tumors.

Authors:  Agnès Maillet; Laurent Guilleminault; Etienne Lemarié; Stéphanie Lerondel; Nicolas Azzopardi; Jérôme Montharu; Nicolas Congy-Jolivet; Pascale Reverdiau; Brigitte Legrain; Christelle Parent; Dominique-Henri Douvin; José Hureaux; Yves Courty; Michèle De Monte; Patrice Diot; Gilles Paintaud; Alain Le Pape; Hervé Watier; Nathalie Heuzé-Vourc'h
Journal:  Pharm Res       Date:  2011-04-14       Impact factor: 4.200

6.  [Cutaneous lesions due to inhibition of epidermal growth factor receptor].

Authors:  E Bierhoff; H W Seifert; T Dirschka
Journal:  Pathologe       Date:  2006-02       Impact factor: 1.011

Review 7.  Positron emission tomography imaging of cancer biology: current status and future prospects.

Authors:  Kai Chen; Xiaoyuan Chen
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

Review 8.  Monoclonal antibodies to growth factors and growth factor receptors: their diagnostic and therapeutic potential in brain tumors.

Authors:  D M Ashley; S K Batra; D D Bigner
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

9.  Perinatal epidermal growth factor receptor blockade prevents peripheral nerve disruption in a mouse model reminiscent of benign world health organization grade I neurofibroma.

Authors:  Jianqiang Wu; Jason T Crimmins; Kelly R Monk; Jon P Williams; Maureen E Fitzgerald; Susan Tedesco; Nancy Ratner
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

10.  Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor.

Authors:  Hong-Jun Liao; Graham Carpenter
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.